NL-OMON41817已完成不适用
An open-label, randomized crossover study to evaluate the pharmacokinetics, bioavailability, bioequivalence, and food effect following administration of Oxybate Formulations in healthy subjects. - JZP-258 Oxybate BA and FE study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male or female volunteers
- •18 - 45 years, inclusive
- •BMI 18-30 kg/m2, inclusive
- •non smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
An open-label, randomized crossover study to evaluate the effect of ASP1941 on the pharmacokinetics, pharmacodynamics, safety and tolerability of glimepiride in healthy subjects and vice versa.NL-OMON34715Astellas Pharma26
已完成
不适用
A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammatioCOPDJPRN-UMIN000024905Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital25
已完成
3 期
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes10012653Diabetes MellitusdiabetesNL-OMON46820Martini Ziekenhuis20
进行中（未招募）
1 期
Study to evaluate the effect of dapagliflozin, exenatide and their combination on the loss of protein in urine in patients with type 2 diabetesEUCTR2017-004709-42-NLMartini Hospital17
尚未招募
不适用
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetesDiabetes Mellitus Type 2 (DM type II), AlbuminuriaNL-OMON24855niversity Medical Center Groningen (UMCG)17